Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278580 | 1.00 | NPC1 (0.52) | NPC1MEN1KMT2ARAB9APADI4 | |
| SCHEMBL4522131 | 0.86 | RXFP1 (0.41) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL12374658 | 0.82 | NPC1 (0.48) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL2279274 | 0.82 | NPC1 (0.48) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL2280088 | 0.81 | PADI4 (0.48) | NPC1MEN1KMT2ARAB9APADI4 | |
| SCHEMBL2280086 | 0.81 | PADI4 (0.48) | NPC1MEN1KMT2ARAB9APADI4 | |
| SCHEMBL2277561 | 0.81 | RAB9A (0.51) | NPC1MEN1KMT2ARAB9APADI4 | |
| SCHEMBL3528614 | 0.81 | NQO1 (0.56) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL2277552 | 0.81 | RAB9A (0.51) | NPC1MEN1KMT2ARAB9APADI4 | |
| SCHEMBL3528612 | 0.81 | NQO1 (0.56) | NPC1MEN1KMT2ARAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20060211680-A1 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1671948-A1 | CINNAMOYL COMPOUND AND USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211680-A1 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | COL2A1, COL1A1, COL14A1 | NPC1 1610/4885MEN1 3520/4885KMT2A 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.